Latest News for NVO

Authoritative coverage of NVO: earnings, product launches, management updates, regulatory filings, and trusted third‑party analysis to support research and due diligence.

Quick links:Overview•Financial Metrics•Technicals•Returns•Market Cap & EV•Financials

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

fool.com•

6 days ago

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.

fool.com•

Jul 21, 2026

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.

Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the highest dose of its own weight loss drug Zepbound.

Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims

proactiveinvestors.com•

Jul 21, 2026

Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

zacks.com•

Jul 21, 2026

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

barrons.com•

Jul 21, 2026

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.

Novo Sues Rival Lilly Over Weight-Loss Ads

youtube.com•

Jul 21, 2026

Novo Sues Rival Lilly Over Weight-Loss Ads

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

zacks.com•

Jul 21, 2026

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Popular Drug Maker Slams GLP-1 Peer on False Advertising

schaeffersresearch.com•

Jul 21, 2026

Popular Drug Maker Slams GLP-1 Peer on False Advertising

Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs.

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

forbes.com•

Jul 21, 2026

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing

fool.com•

Jul 21, 2026

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing

Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-market yield that is also well above its industry peers.

Nasdaq Futures Jump 357 Points as Earnings Season Heats Up

schaeffersresearch.com•

Jul 21, 2026

Nasdaq Futures Jump 357 Points as Earnings Season Heats Up

Futures on the Dow Jones Industrial Average (DJI) and Nasdaq-100 Index (NDX) are comfortably higher this morning

Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims

invezz.com•

Jul 21, 2026

Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims

Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

marketwatch.com•

Jul 21, 2026

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs

Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs

wsj.com•

Jul 21, 2026

Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

reuters.com•

Jul 21, 2026

Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss ‌medicines outperform Novo's drugs.

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

cnbc.com•

Jul 21, 2026

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker's rival injections. Novo Nordisk is specifically taking issue with nationwide ads that cite what it called "outdated" clinical trials to compare the highest doses of Lilly's medicines to lower doses of Novo's drugs.

Social Sentiment

Want to see how the market feels about NVO? View real-time social sentiment analysis from Twitter and StockTwits to gauge crowd psychology and potential price impacts.

View Social Sentiment